Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling – a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial

Fig. 2

Patient enrollment status in ProTarget. The figure illustrates the number of molecular tumor profiles (Total MTB) assessed at the DN-MTB, and for ProTarget: the number of pre-screened pts. (Prescreen), number of pts. with informed consent (Consented), and number of pts. enrolled in treatment from study start 24-AUG-2020 to cut-off date 01-JUL-2022

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us